- Home
- FMN vs MAIA Comparison
FMN vs MAIA Comparison
Compare FMN & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMN | MAIA |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.8M | 89.7M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | FMN | MAIA |
|---|---|---|
| Price | $10.87 | $1.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.1K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | ★ 29.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.11 | $0.87 |
| 52 Week High | $11.38 | $3.19 |
Technical Indicators
Market Signals| Indicator | FMN | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 22.74 | 38.07 |
| Support Level | $10.49 | $1.44 |
| Resistance Level | $11.29 | $1.74 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 1.08 | 48.19 |
Price Performance
Historical ComparisonAbout FMN Federated Hermes Premier Municipal Income Fund
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.